Skip to main content
. Author manuscript; available in PMC: 2022 Mar 24.
Published in final edited form as: Chem Rev. 2021 Jan 28;121(6):3271–3296. doi: 10.1021/acs.chemrev.0c00967

Table 3.

Half-Lives of Potential Long-Acting Drugs

median terminal half-lives ref
rilpivirine (RPV) 50 h 302
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/202022s008lbledt.pdf
tenofovir alafenamide (TAF) 92 min* *in dogs
119
TFV-DP (active metabolite of TAF) 50−180 h 303,304
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/207561s002lbl.pdf
islatravir (EFdA) 78.5−128 h 299